Publicaciones

International Journal of Neuropsychopharmacology 2016

Alvarez XA, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M, Linares C, Granizo E, Garcia-Fantini M, Marey J, Masliah E, Winter S, Muresanu D, Moessler H. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. International Journal of Neuropsychopharmacology 2016; doi: 10.1093/ijnp/pyw024

Ver Publicación

01 Ene, 2016

NS Neurol Disord Drug Targets 2015

Muresanu DF, Ciurea AV, Gorgan RM, Gheorghita E, Florian SI, Stan H, Blaga A, Ianovici N, Iencean SM, Turliuc D, Davidescu HB, Mihalache C, Brehar FM, Mihaescu AS, Mardare DC, Anghelescu A, Chiparus C, Lapadat M, Pruna V, Mohan D, Costea C, Costea D, Palade C, Bucur N, Figueroa J, Alvarez A. A retrospective, multi-center cohort study evaluating the severity- related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. CNS Neurol Disord Drug Targets 2015;14(5):587-599.

Ver Publicación

29 Jun, 2015

Journal of Alzheimer’s Disease 2014

Alvarez XA, Aleixandre M, Linares C, Masliah E, Moessler H. Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer’s disease. Journal of Alzheimer’s Disease 2014; 42:1347-1355

Ver Publicación

04 Jul, 2014

Future Neurology 2013

Alvarez XA, Figueroa J, Muresanu D. Peptidergic drugs for treatment of traumatic brain injury. Future Neurology 2013;8(2):175–192

Ver Publicación

04 Jul, 2013

European Neurological Review 2012

Alvarez XA, Linares C, Masliah E. Combination drug therapy for the treatment of Alzheimer’s disease. European Neurological Review 2012;7(2):92–102

Ver Publicación

01 Jul, 2012

Drugs Today 2011

Alvarez XA, Fuentes P. Cerebrolysin in Alzheimer’s disease. Drugs Today 2011;47(7):487-513.

Ver Publicación

10 Jul, 2011

J Neurosci Res 2011

Rockenstein E, Ubhi K, Pham E, Michael S, Doppler E, Novak P, Inglis C, Mante M, Adame A, Alvarez XA, Moessler H, Masliah E. Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease. J Neurosci Res 2011;89(11):1812-21.

Ver Publicación

04 Jul, 2011

Eur J Neurology 2011

Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer_s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurology 2011;18:59-68.

Ver Publicación

04 Mar, 2011

Current Alzheimer Research 2011

Alvarez XA, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M, Linares C, Granizo E, García-Fantini M, Beurecht W, Doppler E, Moessler H. Combination Treatment in Alzheimer’s Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil. Current Alzheimer Research 2011; 8:593-591

Ver Publicación

04 Mar, 2011

J Neurol Sci 2010

Muresanu DF, Alvarez XA, Moessler H, Novak PH, Stan A, Buzoianu A, Bajenaru O, Popescu BO. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. J Neurol Sci 2010;299(1-2):179-183.

Ver Publicación

04 Jul, 2010


Page 1 of 3 123